Michael D. Howell, PhD, Founder and PresidentThe firm works at the intersection of science and strategy, shaping research and development plans, aligning with regulatory and investor expectations, and enabling smooth progression through each phase. Throughout their careers, the team has supported more than nine approved therapies, including OPZELURA®, JAKAFI®, SPEVIGO®, SKYRIZI®, TEZSPIRE®, and ADBRY®.
“We personally invest in each client relationship, committed to building partnerships that last,” says Michael D. Howell, founder and president.
Mountaineer Biosciences is led by Michael Howell, PhD, and Ashley R. Murray-Howell, PhD, who bring decades of scientific and translational expertise across the drug development lifecycle. Dr. Howell brings deep expertise in immune system modulation, helping clients determine which disease mechanisms to pursue based on their therapeutic approach. Dr. Murray-Howell applies her background in pharmacology, physiology and metabolic science to lead translational planning, scientific due diligence and program evaluation. Together, they provide the strategic and scientific leadership typically delivered by the Chief Scientific Officer and Chief Development Officer.
Built to Fill a Critical Gap in Scientific Leadership
Mountaineer Biosciences was founded during the COVID-19 pandemic, a time when many pharmaceutical R&D divisions were downsized or restructured to focus on vaccines and high-priority public health needs. Inflammation and immunology programs, particularly those in early or translational stages, were left with limited access to scientific leadership.
At the time, Michael had already earned a reputation as a respected advisor across industry and academia. A former faculty member at National Jewish Health, he played a central role in interrogating the mechanisms underlying atopic dermatitis and asthma—contributions that laid the groundwork for multiple now-approved therapies. Growing demand for his guidance led to the formal creation of Mountaineer Biosciences.
Over the years, Michael has built strong relationships with physicians, translational scientists and key opinion leaders across the field. Today, Mountaineer Biosciences draws on this trusted network to strengthen strategic evaluations, enabling the firm to access hard-to-reach data, pressure-test ideas and shape development plans with a high degree of scientific credibility.
Mountaineer Biosciences’ support continues through development and preclinical planning. It helps clients design clinical development plans, define biomarker strategies and implement patient stratification frameworks. Backed by several patents in these areas, the team provides targeted guidance on experimental design and ensures translational alignment from the earliest stages.
Aligning Scientific Rigor with Real-World Milestones
Clarity and speed in scientific decision-making are Mountaineer Biosciences’ hallmark. The firm begins by understanding each client’s broader vision, whether it’s becoming a major biotech or securing capital to reach key clinical milestones. It then dives into the science to evaluate programs, helping clients identify the right indication, refine disease targets and uncover complementary biological pathways that may enhance the therapeutic strategy.
-
We personally invest in each client relationship, committed to building partnerships that last
Mountaineer Biosciences’ support continues through development and preclinical planning. It helps clients design clinical development plans, define biomarker strategies and implement patient stratification frameworks. Backed by several patents in these areas, the team provides targeted guidance on experimental design and ensures translational alignment from the earliest stages.
The firm also collaborates with venture capital partners to co-found early-stage biotech companies, shaping discovery programs and securing seed funding for novel therapeutics focused companies. In these ventures, Mountaineer Biosciences applies its scientific rigor to review all documentation, synthesize core program strengths and craft compelling narratives that speak clearly to both investors and regulators.
In one recent engagement, Mountaineer Biosciences supported an immunology startup working in a novel therapeutic space. The firm guided the client through development of a comprehensive mechanism-of-action strategy, clarifying the science behind the molecule and shaping a clear translational and clinical path. From detailed slide decks and white papers to targeted educational materials, Mountaineer Biosciences equipped the client with tools to communicate effectively with investors and physicians.
With Mountaineer Biosciences as a trusted partner, biopharma and biotech companies make confident, science-driven decisions that accelerate development and lead to therapeutic breakthroughs.
Choosing a Drug Development Consulting Firm
Biotech executives rarely struggle with ambition. The more difficult challenge is exercising validated judgment at the point where science, capital, and clinical execution intersect. A promising target can lose momentum quickly when indication selection is too broad, biomarker rationale is underdeveloped, investor materials overstate the biology, or clinical planning diverges from what physicians and regulators will ultimately require. A consultant who has additional operational capacity to offer is not our most valuable. Our most valuable asset is the one who can work with management to determine which scientific narrative is sustainable, which developmental route deserves resources and which pieces of data are lacking in order to move the program forward.
That judgment has become increasingly difficult in today’s market. Many emerging biotech companies operate with lean internal teams, fractional leadership structures, and pressure to reach financing or clinical milestones without prematurely building a full development organization. Large companies face a variant of this problem: Portfolio decisions must compete for a place on already crowded therapeutic and ever-more exacting patient-selection ground. A good adviser has to link discovery science to translational evidence, clinical feasibility, and commercial sense, and it must do so without shoehorning every sponsor into a templated development process.
Strong drug development consulting begins with understanding the sponsor’s actual objective. A company preparing for seed financing, a team moving toward an IND submission, and an organization refining a commercial differentiation strategy require fundamentally different guidance. A competent consulting partner knows whether the leadership is building a long-term biotech company, getting an asset ready for partnering, or wanting to raise the next financing tranche. The context dictates how to understand the science, the amount of data required and how to craft the development story for the investors, clinician, regulator or company internally.
Scientific depth remains the defining test. Drug development guidance becomes weak when pathways are treated as abstract concepts rather than biological systems connected to disease selection, patient segmentation, and measurable response. Executives should look for advisers capable of rigorously evaluating the mechanism of action, comparing indication opportunities, identifying translational biomarkers, and making preclinical work more informative for future human studies. A top-tier firm should also be adept at assessing where the value of a program can exist in terms of creating a sound linkage between biology, an unmet clinical need, and a viable path into the clinic rather than making expansive target claims.
Network quality is also a relevant consideration; however, it is only useful when it leads to better decisions. Access to KOL's, investigators, venture groups and commercial strategists creates value when it challenges assumptions, trial designs, and competitive positioning at an appropriate point. Value is created far less effectively when it is merely translated into industry reputation. Effective consulting partners introduce external expertise at the right stage and translate that input into practical recommendations around disease focus, clinical strategy, financing materials, and partnership planning.
For executives evaluating firms in this category, Mountaineer Biosciences deserves serious consideration. The company operates as a boutique scientific consulting firm with experience spanning drug development, translational research, clinical development, business development, and commercial launch strategy. Its capabilities align closely with the needs of biotech sponsors, including target identification, biomarker discovery, translational and personalized medicine, clinical development planning, data analysis, pipeline review, due diligence, pharmacovigilance, and competitive landscape assessment. Its therapeutic profile across allergy, autoimmunity and inflammation, dermatology, hematology and oncology and respiratory disease offers particular appeal to complex therapeutic developers. Mountaineer Biosciences will therefore be of significant relevance to organizations looking to gain expert scientific opinion, a concentrated development strategy, and a credible path from biological hypothesis through to clinical implementation.
...Read more
Drug Development Consulting Info
Q1
What distinguishes Mountaineer Biosciences among Top Drug Development Consulting Firms?
Mountaineer Biosciences has earned recognition among Top Drug Development Consulting Firms through its highly specialized focus on inflammation and immunology therapeutics. The company combines translational science expertise with strategic drug development guidance to help biotechnology and biopharmaceutical organizations move therapies from discovery through commercialization. Its leadership team brings experience connected to multiple approved therapies including OPZELURA®, JAKAFI®, SKYRIZI® and TEZSPIRE®. Mountaineer Biosciences also differentiates itself through a hands-on consulting model that integrates scientific rigor, biomarker strategy and clinical development planning within one collaborative framework.
Q2
How does Mountaineer Biosciences approach drug development consulting?
Scientific precision and long-term partnership building shape the company’s consulting philosophy. Unlike many Drug Development Consulting Firms that separate strategic advisory from scientific execution, Mountaineer Biosciences combines both disciplines throughout the development lifecycle. The company supports target identification, biomarker discovery, translational planning, patient stratification and clinical development strategy while aligning programs with regulatory and investor expectations. Its consulting approach also emphasizes early scientific validation and disease mechanism analysis, helping clients refine therapeutic direction before advancing into costly development stages.
Q3
Why is Mountaineer Biosciences relevant to emerging biotechnology companies?
Biotechnology startups often face limited access to experienced scientific leadership during early-stage development, especially in specialized therapeutic areas such as immunology and inflammation. Mountaineer Biosciences addresses this gap by providing strategic and translational expertise typically associated with senior in-house scientific leadership teams. Among Drug Development Consulting Firms, the company stands out for supporting emerging biopharma organizations with program evaluation, translational research planning and investor-facing scientific communication. Its ability to help companies define clear development pathways strengthens decision-making during critical growth stages.
Q4
What role does translational science play at Mountaineer Biosciences?
Translational science remains central to the company’s consulting model. Mountaineer Biosciences uses disease biology, biomarker analysis and mechanistic research to connect discovery-stage science with clinical development strategies. Its expertise in inflammation and immunology allows the company to guide clients toward therapeutically relevant disease targets and patient stratification frameworks that improve development precision. Drug Development Consulting Firms often differentiate themselves through therapeutic specialization, and Mountaineer Biosciences reinforces that distinction through deep immunology expertise supported by scientific publications, patents and translational development experience.
Q5
How does Mountaineer Biosciences support clients beyond scientific consulting?
Strategic collaboration extends beyond laboratory science at Mountaineer Biosciences. The company supports clients with due diligence preparation, investor communications, white papers, scientific presentations and development narratives designed for regulatory and commercial audiences. Its team also collaborates with venture capital partners to help establish early-stage biotechnology ventures focused on novel therapeutics. Among Drug Development Consulting Firms, Mountaineer Biosciences distinguishes itself through its ability to integrate scientific credibility with business-focused development strategy and partnership support.
Q6
Why has Mountaineer Biosciences gained industry recognition in drug development consulting?
Industry recognition for Mountaineer Biosciences reflects its combination of scientific leadership, translational expertise and therapeutic development success across immunology and inflammation programs. The company has contributed to therapies that achieved regulatory approval while continuing to support emerging biotechnology innovation through strategic consulting and precision medicine initiatives. Its recent involvement in the launch of the Subtilitas precision translational medicine platform also demonstrates continued investment in biomarker discovery and clinical research advancement. This combination of scientific depth, translational insight and collaborative consulting continues to strengthen Mountaineer Biosciences’ reputation among Drug Development Consulting Firms.
